Events

Sustainable Economy in Horizon Europe - International INSE 2024
OCT
Wed
23
OCT
Thu
24

This was 1 year ago

Location

Warsaw, Poland

Sheraton Grand Warsaw, Bolesława Prusa 2 Street
Programmes
Climate, Energy, Mobility

The Sustainable Economy in Horizon Europe INSE 2024 event is a unique opportunity to establish direct contact between researchers and entrepreneurs. The formula of the event is based on: Pitching, Networking and Matchmaking sessions.

Date 23rd - 24th October 2024

Format: On-site only (no virtual participation)

The event is focused on areas related to sustainable economy in particular on the:

  • Capabilities of the Polish industry within the European ecosystem
  • Infrastructure for sustainable economy
  • Technologies, raw materials and advanced materials for defense and civil applications
  • Partnerships in Horizon Europe and the benefits of participating in them
  • Hubs4Circularity
  • New technologies for the recovery of metals and critical raw materials
  • Sustainable construction
  • Clean energy & clean mobility
  • Innovative solutions for transport

For more information and to register for this event, please visit the dedicated page.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.